PT3023788T - Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores - Google Patents

Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores

Info

Publication number
PT3023788T
PT3023788T PT151982840T PT15198284T PT3023788T PT 3023788 T PT3023788 T PT 3023788T PT 151982840 T PT151982840 T PT 151982840T PT 15198284 T PT15198284 T PT 15198284T PT 3023788 T PT3023788 T PT 3023788T
Authority
PT
Portugal
Prior art keywords
compositions
tumor specific
specific neoantigens
neoantigens
tumor
Prior art date
Application number
PT151982840T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Massachusetts Gen Hospital
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44915022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3023788(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Gen Hospital, Dana Farber Cancer Inst Inc filed Critical Massachusetts Gen Hospital
Publication of PT3023788T publication Critical patent/PT3023788T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
PT151982840T 2010-05-14 2011-05-16 Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores PT3023788T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33486610P 2010-05-14 2010-05-14

Publications (1)

Publication Number Publication Date
PT3023788T true PT3023788T (pt) 2020-05-18

Family

ID=44915022

Family Applications (1)

Application Number Title Priority Date Filing Date
PT151982840T PT3023788T (pt) 2010-05-14 2011-05-16 Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores

Country Status (14)

Country Link
US (8) US9115402B2 (enExample)
EP (4) EP4623996A2 (enExample)
JP (5) JP5948319B2 (enExample)
KR (4) KR102447139B1 (enExample)
CN (2) CN103180730B (enExample)
AU (1) AU2011252795B2 (enExample)
BR (2) BR112012029066A2 (enExample)
CA (2) CA3197245A1 (enExample)
DK (1) DK3023788T3 (enExample)
ES (3) ES2788863T3 (enExample)
HU (1) HUE049886T2 (enExample)
PL (1) PL3023788T3 (enExample)
PT (1) PT3023788T (enExample)
WO (1) WO2011143656A2 (enExample)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
HUE049886T2 (hu) 2010-05-14 2020-10-28 Massachusetts Gen Hospital Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
ES2746233T3 (es) * 2011-05-24 2020-03-05 Biontech Rna Pharmaceuticals Gmbh Vacunas individualizadas para el cáncer
EP3892295B1 (en) * 2011-05-24 2023-04-26 BioNTech SE Individualized vaccines for cancer
EP2757153B1 (en) * 2011-08-02 2019-07-03 The University of Tokyo Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor
JP2014530013A (ja) * 2011-09-29 2014-11-17 トローバジーン インコーポレイテッド Ｓｆ３ｂ１遺伝子における変異および慢性リンパ性白血病
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10640535B2 (en) 2012-05-25 2020-05-05 Agenus Inc. Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
AU2013308409A1 (en) * 2012-08-31 2015-03-26 University Of Birmingham Target peptides for immunotherapy and diagnostics
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
EP2901341B1 (en) 2012-09-28 2019-04-10 The University of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
CA2892391C (en) 2012-11-28 2023-10-17 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
ES2739913T3 (es) 2013-02-22 2020-02-04 Curevac Ag Combinación de vacunación e inhibición de la ruta PD-1
EP2958588B1 (en) 2013-02-22 2017-08-23 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
EP2970907B1 (en) 2013-03-14 2020-01-01 The Johns Hopkins University Nanoscale artificial antigen presenting cells
JP6702855B2 (ja) * 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP4052724A1 (en) * 2013-12-06 2022-09-07 The Broad Institute Inc. Formulations for neoplasia vaccines
BR112016014410A2 (pt) * 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
US20160326597A1 (en) * 2014-01-02 2016-11-10 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
CN107076762B (zh) * 2014-09-10 2021-09-10 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
AU2015315559A1 (en) * 2014-09-10 2017-02-16 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016040900A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
PT3193917T (pt) * 2014-09-17 2021-10-20 Io Biotech Aps Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta
SG11201702191YA (en) * 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
EP4029508A1 (en) * 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2016174085A1 (en) * 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer
CA2984234C (en) 2015-05-01 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
BR112017024797A2 (pt) * 2015-05-20 2018-08-07 The Broad Institute Inc. neoantígenos partilhados
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3323070B1 (en) * 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
HK1258649A1 (zh) * 2015-09-18 2019-11-15 Baylor College Of Medicine 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR102770755B1 (ko) * 2015-10-12 2025-02-21 난토믹스, 엘엘씨 바이러스 네오에피토프 및 이의 용도
EP3362103B1 (en) 2015-10-12 2025-01-22 Nantomics, LLC Compositions and methods for viral cancer neoepitopes
AU2016339022B2 (en) * 2015-10-12 2020-09-10 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
EP3362930A4 (en) * 2015-10-12 2019-06-19 Nantomics, LLC SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS
US20180318409A1 (en) * 2015-10-22 2018-11-08 Modernatx, Inc. Cancer vaccines
RU2743169C2 (ru) 2015-11-06 2021-02-15 Вентана Медикал Системз, Инк. Репрезентативная диагностика
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
SG11201804957VA (en) * 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
CA3048193A1 (en) * 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN108701172A (zh) * 2016-02-12 2018-10-23 南托米克斯有限责任公司 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点
US11585805B2 (en) 2016-02-19 2023-02-21 Nantcell, Inc. Methods of immunogenic modulation
CN105720176A (zh) * 2016-02-19 2016-06-29 京东方科技集团股份有限公司 一种胶囊量子点和发光二极管、制备方法及显示装置
AU2017281126A1 (en) * 2016-03-24 2018-10-04 Nant Holdings Ip, Llc Sequence arrangements and sequences for neoepitope presentation
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US20190062272A1 (en) * 2016-04-13 2019-02-28 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
CA3028721A1 (en) 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US20190247435A1 (en) * 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
HUE056660T2 (hu) * 2016-07-20 2022-03-28 BioNTech SE A neoepitópok mint betegségspecifikus célpontok kiválasztása a fokozott hatékonyságú terápia számára
EP3493836A4 (en) * 2016-08-02 2020-03-04 Nantcell, Inc. TRANSFECTION OF DENDRITIC CELLS AND RELATED METHODS
WO2018045249A1 (en) * 2016-08-31 2018-03-08 Medgenome, Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
WO2018053242A1 (en) 2016-09-15 2018-03-22 Idera Pharmaceuticals, Inc. Immune modulation with tlr9 agonists for cancer treatment
WO2018057447A1 (en) * 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
WO2018071796A2 (en) * 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
EP4338799A3 (en) * 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US20190321481A1 (en) 2016-11-11 2019-10-24 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
AU2017367696A1 (en) 2016-12-01 2019-06-20 Nant Holdings Ip, Llc Tumor antigenicity processing and presentation
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7731656B2 (ja) * 2017-02-01 2025-09-01 モデルナティエックス インコーポレイテッド Ｒｎａ癌ワクチン
AU2018214556A1 (en) * 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
WO2018175505A1 (en) * 2017-03-20 2018-09-27 Genocea Biosciences, Inc. Treatment methods
WO2018183544A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Method for identification of retained intron tumor neoantigens from patient transcriptome
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
CA3057715A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CA3060569A1 (en) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
EP3615675A4 (en) 2017-04-24 2021-03-03 Nantcell, Inc. TARGETED NEO-EPITOPIC VECTORS AND ASSOCIATED PROCESSES
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3622068B1 (en) 2017-05-10 2024-02-28 The Broad Institute, Inc. Methods for determination of mutations in single replication events
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
EP3630131B1 (en) * 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized canine cancer vaccines
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2018287159B2 (en) * 2017-06-21 2025-01-16 Transgene Personalized vaccine
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
TWI832820B (zh) 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
WO2019023269A1 (en) 2017-07-25 2019-01-31 California Institute Of Technology DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
WO2019036043A2 (en) * 2017-08-16 2019-02-21 Medgenome Inc. METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
US20200362418A1 (en) * 2017-10-02 2020-11-19 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
RU2020115161A (ru) * 2017-10-06 2021-11-08 Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи Днк моноклональных антител против ctla-4 для лечения и профилактики рака
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
JP7357613B2 (ja) * 2017-11-06 2023-10-06 ラディック インスティテュート フォア キャンサー リサーチ リミテッド リンパ球の拡大方法
EP3706770A4 (en) * 2017-11-07 2021-10-27 Nektar Therapeutics IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER
CN120519386A (zh) 2017-11-08 2025-08-22 百欧恩泰美国公司 T细胞制备组合物和方法
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
CN109682978B (zh) * 2017-11-30 2020-07-03 四川康德赛医疗科技有限公司 一种肿瘤突变肽mhc亲和力预测方法及其应用
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN111818943B (zh) 2018-01-04 2024-09-03 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
US20210046177A1 (en) 2018-01-26 2021-02-18 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
KR20200127001A (ko) * 2018-02-27 2020-11-09 그릿스톤 온콜로지, 인코포레이티드 범-대립유전자 모델을 갖는 신생항원 동정
TW202012430A (zh) 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質－結合之胜肽組成物及其使用方法
KR20210018321A (ko) * 2018-05-25 2021-02-17 더 위스타 인스티튜트 종양 특이적 신생항원 및 이를 사용하는 방법
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US12391736B2 (en) 2018-07-26 2025-08-19 Curevac Netherlands B.V. Off-the-shelf cancer vaccines
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
IL321692A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for colorectal cancer
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN112930569B (zh) 2018-08-31 2025-10-03 夸登特健康公司 无细胞dna中的微卫星不稳定性检测
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
TW202028224A (zh) * 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202027761A (zh) 2018-09-21 2020-08-01 美商柏克萊燈光有限公司 功能化孔盤、其製備方法及用途
SG11202101965QA (en) 2018-09-27 2021-04-29 Vaccibody As Method for selecting neoepitopes
EP3867353A4 (en) 2018-10-18 2022-07-27 Berkeley Lights, Inc. PROTO-ANTIGEN PRESENTING SYNTHETIC SURFACES, ACTIVATED T-CELLS AND THEIR USES
US20200188435A1 (en) 2018-11-08 2020-06-18 Nexlmmune, Inc. T cell compositions with improved phenotypic properties
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
MX2021010089A (es) 2019-02-20 2021-12-10 Rubius Therapeutics Inc Células eritroides diseñadas que incluyen polipéptidos que presentan antígeno cargable y métodos de uso.
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
US12427195B1 (en) * 2019-03-11 2025-09-30 La Jolla Institute For Immunology Methods of neoantigen identification
WO2020185010A1 (ko) * 2019-03-12 2020-09-17 (주)신테카바이오 인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
EP3963335B1 (en) * 2019-05-03 2024-08-21 Epivax Therapeutics, Inc. Neoantigens in cancer
EP3966323A4 (en) * 2019-05-06 2024-04-24 The Regents Of The University Of Michigan TARGETED THERAPY
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CN110322925B (zh) * 2019-07-18 2021-09-03 杭州纽安津生物科技有限公司 一种预测融合基因产生新生抗原的方法
CN110706747B (zh) * 2019-09-17 2021-09-07 北京橡鑫生物科技有限公司 检测肿瘤新生抗原多肽的方法和装置
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
US20230210968A1 (en) 2020-06-11 2023-07-06 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
AU2021325081A1 (en) 2020-08-13 2023-04-13 Biontech Us Inc. T cell manufacturing compositions and methods
GB2613718A (en) * 2020-08-31 2023-06-14 World Biotech Regenerative Medical Group Ltd Personalized immunogenic compositions and methods for producing and using same
KR102552632B1 (ko) * 2020-11-06 2023-07-06 사회복지법인 삼성생명공익재단 중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
EP4313129A4 (en) * 2021-03-26 2025-05-14 The Translational Genomics Research Institute METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES
EP4330380A1 (en) 2021-04-30 2024-03-06 Tigen Pharma SA Single vessel expansion of lymphocytes
WO2022251034A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Multicomponent chemical composition of a peptide-based neoantigen vaccine
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
CN115772564B (zh) * 2021-09-08 2023-08-18 广州市基准医疗有限责任公司 用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
EP4419716A1 (en) 2021-10-21 2024-08-28 CureVac Netherlands B.V. Cancer neoantigens
CN116287158A (zh) * 2021-12-08 2023-06-23 初源海生物科技(深圳)有限公司 一种新抗原鉴定和疗效预测方法
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4612276A1 (en) 2022-11-02 2025-09-10 Tigen Pharma SA Expansion of lymphocytes
EP4474016A1 (en) 2023-06-07 2024-12-11 Julius-Maximilians-Universität Würzburg Strategies to target extracellularly accessible ras protein
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US911A (en) 1838-09-12 Mode of fastening bedsteabs
US221332A (en) 1879-11-04 Improvement in fire-escapes
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5589406A (en) 1993-07-30 1996-12-31 Ag Technology Co., Ltd. Method of making TFT display
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
KR20010083890A (ko) * 1998-10-05 2001-09-03 에드워드 에이. 맥더모트, 주니어 암 관련 항원 및 그의 용도
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CA2374237A1 (en) * 1999-05-06 2000-11-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
US20060073150A1 (en) * 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
AU5898400A (en) * 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
WO2001055177A2 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Methods to identify ctl epitopes of hiv
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
PT1512014E (pt) 2002-06-13 2009-11-10 Merck Patent Gmbh Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante
JP5156882B2 (ja) * 2003-04-18 2013-03-06 アイディーエム ファーマ，インコーポレイティド Ｈｌａ−ａ２腫瘍関連抗原ペプチドおよび組成物
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
EP1994181A4 (en) 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US9045556B2 (en) 2007-02-07 2015-06-02 Nec Corporation Therapeutic agent for cancer
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
US8598125B2 (en) 2007-08-20 2013-12-03 Onco Therapy Science, Inc. CDCA1 peptide and pharmaceutical agent comprising the same
EP2238265A4 (en) 2007-12-28 2012-01-18 Wayne John Cancer Inst USE OF THE METHYLATION STATE OF MINT-LOCI AND TUMOR ASSOCIATED GENES AS A MARKER FOR MELANOMA AND MAMMARIAN CARCINOMA
US20110097312A1 (en) * 2008-02-15 2011-04-28 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2010033949A1 (en) * 2008-09-22 2010-03-25 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US8369279B2 (en) 2010-03-10 2013-02-05 Broadcom Corporation Method and system for iterative multiple frequency hypothesis testing with cell-ID detection in an E-UTRA/LTE UE receiver
ES2742263T3 (es) 2009-12-10 2020-02-13 Merck Patent Gmbh Composiciones farmacéuticas que comprenden oligopéptidos, preferiblemente cilengitida
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
HUE049886T2 (hu) 2010-05-14 2020-10-28 Massachusetts Gen Hospital Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
RU2621640C2 (ru) 2010-06-02 2017-06-06 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
AU2012206487A1 (en) 2011-01-14 2013-07-18 Genefirst Limited Methods, compositions, and kits for determining the presence/absence of a variant nucleic acid sequence
KR20140057343A (ko) 2011-08-18 2014-05-12 네스텍 소시에테아노님 대립형질 변이 검출을 위한 조성물 및 방법
US20160130641A1 (en) 2012-02-15 2016-05-12 Janssen Diagnostics, Llc Highly sensitive method for detecting low frequency mutations
IL318221A (en) 2012-05-15 2025-03-01 Bristol Myers Squibb Co Cancer immunotherapy by disrupting PD–1/PD–L1 signaling
WO2014150924A2 (en) 2013-03-15 2014-09-25 The Broad Institute, Inc. Accurate typing of hla through exome sequencing
AU2015268982B2 (en) 2014-06-05 2021-11-04 Kling Biotherapeutics B.V. Means and methods for determining T cell recognition
CA2957396C (en) 2014-08-07 2021-03-09 Evrykleia LIANIDOU Method of determining pik3ca mutational status in a sample
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
WO2016183042A1 (en) 2015-05-10 2016-11-17 Quandx Inc. Ultra sensitive probes for detection of nucleic acid
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法

Also Published As

Publication number Publication date
EP3699266B1 (en) 2025-07-02
US20160008447A1 (en) 2016-01-14
KR102315754B1 (ko) 2021-10-22
BR122021014039B1 (pt) 2021-12-14
JP2016156828A (ja) 2016-09-01
ES2564841T3 (es) 2016-03-29
EP3699266A1 (en) 2020-08-26
JP2024045573A (ja) 2024-04-02
KR102447139B1 (ko) 2022-09-23
US20110293637A1 (en) 2011-12-01
EP3023788A1 (en) 2016-05-25
US20200069783A1 (en) 2020-03-05
KR20180105743A (ko) 2018-09-28
JP6943545B2 (ja) 2021-10-06
KR102095670B1 (ko) 2020-03-31
EP2569633B1 (en) 2016-02-10
US20200016251A1 (en) 2020-01-16
CN103180730B (zh) 2016-03-02
AU2011252795A1 (en) 2012-11-08
EP2569633A2 (en) 2013-03-20
CA3197245A1 (en) 2011-11-17
KR20190133281A (ko) 2019-12-02
JP2013530943A (ja) 2013-08-01
ES2788863T3 (es) 2020-10-23
KR20130119845A (ko) 2013-11-01
EP4623996A2 (en) 2025-10-01
WO2011143656A3 (en) 2012-08-23
JP7008049B2 (ja) 2022-02-10
JP2019135494A (ja) 2019-08-15
KR102017898B1 (ko) 2019-09-04
US20190060432A1 (en) 2019-02-28
CN105648056A (zh) 2016-06-08
ES3038392T3 (en) 2025-10-13
BR112012029066A2 (pt) 2020-09-01
CA2797868A1 (en) 2011-11-17
CN103180730A (zh) 2013-06-26
US9115402B2 (en) 2015-08-25
EP2569633A4 (en) 2014-05-14
WO2011143656A2 (en) 2011-11-17
AU2011252795B2 (en) 2015-09-03
US20180055922A1 (en) 2018-03-01
EP3023788B1 (en) 2020-02-12
HUE049886T2 (hu) 2020-10-28
PL3023788T3 (pl) 2020-07-27
JP5948319B2 (ja) 2016-07-06
DK3023788T3 (da) 2020-04-27
US20160331822A1 (en) 2016-11-17
CA2797868C (en) 2023-06-20
US10426824B1 (en) 2019-10-01
JP2022044632A (ja) 2022-03-17
KR20210129254A (ko) 2021-10-27

Similar Documents

Publication Publication Date Title
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
GB201002983D0 (en) Nutritinal composition
GB201006699D0 (en) Composition
GB201006178D0 (en) Composition
EP2554608A4 (en) METAL PIGMENT COMPOSITION
GB201017048D0 (en) Composition
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
ZA201206841B (en) Novel composition
GB201016970D0 (en) Composition
PL2407155T3 (pl) Formulacje inekalcytolu
IL223926A0 (en) Synthesis of cyclopentaquinazolines
GB201019988D0 (en) Composition
GB201005927D0 (en) Improved composition
GB201007531D0 (en) Composition
GB201006214D0 (en) Composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
IL222903A0 (en) Composition of small molecule therapeutices
GB201014967D0 (en) Composition
GB201010657D0 (en) Composition
GB201018130D0 (en) Composition
GB201006175D0 (en) Composition
GB201006182D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition